The ASX-listed pharmaceutical giant has shrugged off a sluggish period and says it expects profits to rise by more than 10 ...

Q2 2025 Management View CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL ...

A weak vaccine result dragged on CSL's H1 result but analysts focus on an improving plasma product margin and solid growth ...

CSL delivered a messy result. Although they did say they are on track to achieve FY guidance, gross margins and 1H adjusted ...

CSL (ASX: CSL) shares fell 4.9% on Tuesday following the company’s report of weaker-than-expected first-half revenue, net ...

SCOTTSDALE, Ariz., February 12, 2025--Carlisle Companies Incorporated (NYSE:CSL) is reinforcing its commitment to innovation through the development and execution of its new innovation accelerator ...

UBS believes the CSL shares story is "heavily focused on gross profit margin improvement" at Behring. According to CSL, that division develops and delivers "high-quality medicines that treat ...

Today, the fund is underweight in CSL. Firetail said: Today our position is well below index weight due to our loss of confidence in the medium-term margin improvement story playing out as we had ...